SlideShare a Scribd company logo
Myelodysplastic Syndrome
Dr Tamil Nila
Postgraduate
Definition
Group of clonal hematopoietic stem cell diseases characterised by
• Cytopenia (atleast 1 lineage)
• Hb < 10g/dl
• Platelet count < 1 lakh/cu.mm
• ANC < 1800 cells/cu.mm
• Monocytes < 1000/cu.mm
• dysplasia in one or more of the major myeloid lineages
• Ineffective hematopoiesis
• Recurrent genetic abnormalities
• Increased risk of AML
Hypoplastic MDS
• 10% MDS
• Independent favourable
prognosis
• DD – Aplastic Anemia
• Exclude Acute marrow injury
MDS with Fibrosis
• 10 – 15% of MDS
• Grade 2 – 3 fibrosis
• Excess of Blasts
• Aggressive clinical course
• Bone marrow Biopsy > BMA
• IHC for CD 34
• Different from Primary
Myelofibrosis
• No splenomegaly
• No leucoerythroblastic blood
picture
• Intrasinusoidal hematopoiesis
Epidemiology
• Older adults
• Male preponderance
• Annual incidence = 3 – 5 caser per 1 lakh population
• At least 20 cases per 1 lakh population > 70 yrs
• Median age at presentation
• United Kingdom – 65 yrs
• India – 45 yrs
• Progression to AML – 30 – 35 %
Etiology
• Hereditary
• Down syndrome
• Monosomy 7
• Neurofibromatosis
• Congenital neutropenia
• Mutagen detoxification
• Family history
• Fanconi Anemia
• Dyskeratosis congenita
• Swachman – Diamond syndrome
• Diamond blackfan anemia
• Acquired
• Senescence
• Radiation
• Mutagen/genotoxic
• Chemotherapy
• Benzene exposure
• Cigarette smoking
• Agricultural solvents/chemicals
• Acquired Aplastic Anemia
• PNH
Clinical Features
• Anemia
• Most common – 85%
• Lethargy
• 1/3rd transfusion dependent
• Leucopenia
• Neutropenia – 50%
• Less common
• Recurrent infections
• Thrombocytopenia
• 25 – 30%
• Bleeding manifestations
• Organomegaly
• 15 – 25%
• Auto immune abnormalities
• Cutaneous vasculitis
• Monoarticular arthritis
• Percarditis
• Iritis
• Myositis
• Pleural effusion
Evaluation
• History
• Prior exposure to CT/RT
• Recurrent infections
• Bleeding/Bruising
• Examination
• Pallor/ bruising
• organomegaly
• Blood counts
• Hb, TLC, Platelet count
• RC
• Blood film
• BMA + BM Bx
• IHC
• CD 34
• CD 41
• CD 61
• Immunophenotyping of BM
• Bone marrow cytogenetics
• Biochemical tests
• S. Iron
• S. LDH
• TSH
• Red cell folate & S. B12
• Other tests
• Viral markers
• Autoimmune disease work up
• FLAER for PNH
Exclusion of reactive causes of Dysplasia
• Megaloblastic Anemia
• HIV Infection
• Recent cytotoxic therapy
• Alcoholism
• Severe intercurrent illness
Microscopy – Points to remember
• >2 hrs from collection –
specimen unsatisfactory
• Staining is significant
• Don’t diagnose MDS without
detailed history
• No of cells to count
• PS – 200 cells
• BM – 500 cells
• If Cytopenic - Count from buffy
coat
• PS blasts can be more than BM
blasts in 13% of MDS
• Persistent cytopenia without
dysplasia – Idiopathic cytopenia
of undetermined significane
• MDS associated clonal gene
mutations without dysplasia –
clonal hematopoiesis of
indeterminate potential
• If in doubt – observe patient for
6 months before diagnosis
PS Characteristics of dysplasia - RBC
• Ovalocytosis
• Macrocytosis
• Elliptocytosis
• Stomatocytes
• Tear drop cells
• Nucleated red cells
• Basophilic stippling
• Howell-Jolly bodies
PS Characteristics of Dysplasia - WBC
• Hypolobation
• Hyposegmentation – Pince-nez
type
• Hypogranulation
• Ring shaped nuclei
• Pseudo-Pelger Huet anomaly -
marked clumping of nuclear
chromatin – nuclear hypolobation
• Auer rod
• Irregular contour of nuclei
• Blasts
PS Characteristics of dysplasia - Platelets
• Giant platelets
• Hypogranular platelets
• Agranular platelets
Bone Marrow Aspiration – Hypercellular
BMA Characteristics of dysplasia - RBC
• Megaloblastic erythropoiesis
• Nuclear budding of erythroblasts
• Multinucleation
• Karyorrhexis
• Ring sideroblasts
• > 5 iron granules
• Encircling > 1/3rd nucleus
• Cytoplasmic vacuolation – PAS
+ve
• Increased Iron stores
BMA Characteristics of dysplasia - WBC
• Defective granulation
• Presence of Auer Rods in myeloid
cells
• Maturation arrest at myelocyte stage
• Increase in Monocytoid cells
• ALIP
• Very small/large granules
• Pseudo chediak higashi granules –
Abnormal large granular clumping
• Irregular nuclear hypersegmentation
• CD 34 +ve blasts
BMA Characteristics of dysplasia - Platelets
• >10% Micromegakaryocytes*
• < 15 µm - Size of promyelocyte
• Non/bi lobated nucleus
• Eosinophilic cytoplasm
• Hypogranulation of
megakaryocytes
• Mutliple small nuclei of
megakaryocytes – Pawn ball
• Nuclear Hypolobation
• CD 61 & CD 41 +ve
Bone Marrow Trephine Biopsy
• Cellularity of Marrow
• ALIP
• Reticulin Fibrosis – 20%
• Megakaryocyte Dysplasia
• CD 61
• CD 41
• Lymphoid aggregates
• Hypoplastic MDS
• Neovascularisation –
transformation to AML
ALIP
Blasts in cell clusters located away from
bone trabeculae & Vascular structures
CD 34 +
IHC
Immature, Blast cells CD 34
TdT
CD 117
Erythroblasts Glycophorin A
Megakaryoblasts CD 61
CD 41
Apoptotis Markers TNF – Alpha
Bax
Immunophenotype
• Flow cytometry in CD 34+ve
cells
• Aberrant maturation patterns in
granulopoiesis can predict
morphological dysplasia
• Myeloblasts, monocytoid cells &
maturing myeloid cells – typical
expression related to lineage &
stage of maturation
• In MDS
• Increased/ Decreased expression of
normal antigens
• Asynchronous maturational
expression
• Aberrant antigen expression
• Atleast 3 aberrancies +
Genetic profile
• Isolated 5q deletion alone & 5q deletion + one additional abnormality
• Hypo/non – lobated megakaryocytes
• Macrocytic anemia
• Favourable clinical course
• Loss of 17 p
• pseudo pelget huer anomaly
• TP 53 mutation
• Therapy related
• Unfavourable clinical course
Conventional Karyotyping
Multicolour FISH
Gene sequencing
SNP Array
Genetic profile
• Normal Karyotype
• 50% MDS
• Abnormal Karyotype
• 90% - t-MDS
• 40 – 50% - primary MDS
Neutral
Neutral
Neutral
Pathogenesis
• Aberrations in apoptotic mechanisms – Increased Apoptosis
• Increased Proliferation
• Ineffective Hematopoiesis
• Autocrine production of Angiogenic molecules – Expansion of
leukemic clone
Classification – WHO 2016
Name Dysplasia Cytopenia RS in BM PS blasts BM Blasts
MDS - SLD 1 1 – 2 < 15%SF3B1 <1% <5%
MDS - MLD 2 – 3 1 – 3
MDS – RS – SLD 1 1 – 2 >15%SF3B1
MDS – RS - MLD 2 – 3 1 – 3
MDS with isolated del (5q) 1 – 3 1 – 2 None or any
MDS – EB1 1 – 3 1 – 3 <5% <10%
MDS – EB2 1 – 3 1 – 3 <20% <20%
MDS - U
Name Dysplasia Cytopenia RS PS Blasts BM Blasts
With 1% Blood blasts 1 – 3 1 – 3 None or any 1%ON 2 OCC <5%
With SLD & Pancytopenia 1 3 <1% <5%
Based on defining cytogenetic
abnormality
0 1 – 3 <15%MDS-RS-SLD
FAB Classification
Subtype Abbreviation PS –Blasts BM
Refractory Anemia RA < 1% Blasts < 5% + RS < 15%
RA + Ringed Sideroblasts RARS < 1% Blasts < 5% + RS > 15%
RA + Excess blasts RAEB < 5% Blasts 5 – 20%
RA + Excess blasts in transformation RAEB – t >5% Blasts 20 – 30 % (Auer rods)
Chronic myelomonocytic leukemia CMML <5% + Monocytes >
1000/cu.mm
Any of the above
Acute Myeloid Leukemia AML Variable Blasts > 30 %
MDS – Single lineage dysplasia
• Incidence : 7 – 20% MDS
• Definition
• Unexplained cytopenia/ bicytopenia
• > 10% dysplastic cells in one myeloid lineage
• 2008 edition – Refractory cytopenia with unilineage dysplasia
• Refractory anemia
• Refractory neutropenia
• Refractory thrombocytopenia
• Ringed sideroblasts
• < 15%
• <5% in cases with SF3B1 mutation
No correlation between
cytopenia & dysplasia
MDS – Multi lineage dysplasia
• 1 or >1 cytopenia
• 2 or >2 dysplasia in the myeloid lineages (> 10%)
• 200 erythroid, 200 Neutrophil precursors & 30 megakaryocytes (30 – 40%) to
be examined in the BMA or BM Bx
• Blasts
• Peripheral smear - < 1%
• Bone marrow - <5%
• Auer rods – Absent
• Monocyte count - < 1000 cells/cu.mm
• Marrow fibrosis – 16%
Incidence
30% of all cases
48% of cases without excess blasts
65% along with MDS – RS – MLD
MDS with Ringed sideroblasts
• Incidence: 3 – 11 %
• >15% ringed sideroblasts in the bone marrow
• >5% in case of SF3B1 mutation
• Other subtypes to be excluded
• MDS – RS – SLD – Usually anemia + Erythroid Dysplasia (9982/3)
• MDS – RS – MLD – any number of cytopenias / dysplasias (9993/3)
MDS with Excess Blasts
• < 20% in both Bone Marrow (5 – 19%) & Blood ( 2 – 19%)
• Incidence – 40%
• Hypercellular marrow
• 30 – 50% have clonal genetic abnormalities
EB 1 EB 2
PS Blasts 2 – 4 % 5 – 19%
BM Blasts 5 – 9 % 10 – 19 %
Auer rods Absent Present
Progression to AML 25% 33%
Median Survival 16 months 9 months
Variants
MDS EB & Erythroid Predominance
• Maturing Erythroblasts > 50% of
marrow cells
• Myeloblasts > 20% of non
erythroid nucleated cells
MDS EB & Fibrosis
• 15% show significant degree of
fibrosis
• Therapy related MDS
• Presence of excess blasts
confirmed by IHC – CD 34
• Increased dysplastic
megakaryocytes
• FCM – CD 34 & C-KIT +ve
MDS with isolated del 5q
• Anemia + other cytopenia + Thrombocytosis
• Thrombocytosis in 1/3rd – ½ of cases
• Loss of tumour suppressor genes in the minimally deleted region (q31 –
q33)
• Erythroid hypoplasia
• Dysplastic Megakaryocytic hyperplasia
• Del 5q demonstrated by FISH analysis
• Cases with addl monosomy 7/ Del 7q is included in this category
• Subsets show JAK2 V617F mutation & SF3B1 mutation
• Median survival – 66 – 145 months
• AML transformation < 10 %
MDS - Unclassifiable
• Diagnosed by Exclusion
• Incidence : 6.3% of cases with <5% blasts
• 1% blasts in the blood on 2 separate occasions
• Persistent cytopenia
• < 2% Blasts in blood
• < 5% blast in BM
• < 10% Dysplasia
• Prognosis in cases with 1% blasts
• Median survival – 30 months
• AML Progression – 14%
Childhood MDS
• < 5% of all hematopoietic neoplasms in less than 14 yrs
• Subtypes
• Refractory Cytopenia of childhood (Blasts <5% in BM & <2% in PS)
• Conventional MDS
• MDS – EB
• MDS – RS
• T - MDS
• GATA2 germline mutation is present in 7% primary MDS
• Criteria for diagnosis - MDS (atleast 2)
• Sustained unexplained cytopenia
• Bilineage morphologic dysplasia
• Acquired clonal cytogenetic morphology
• Increased blasts (>5%)
Therapy related MDS
• Late complication of Chemotherapy/ radiotherapy administered for
prior neoplastic or non neoplastic disorder
• Incidence: 10 – 20% of all cases of AML, MDS & MDS/MPN
• Prior history
• 70% for solid tumours (Breast Cancer)
• 30% Hematopoietic neoplasms (Non Hodgkin’s lymphoma)
• Poor Prognosis
Risk factors for t-MDS
International
Prognostic
scoring
system
Very low Low Intermediate High Very High
Patients % 19% 38% 20% 13% 10%
Survival 8.8 5.3 3.0 1.6 0.8
AML transformation Not reported 10.8 3.2 1.4 0.7
Differential Diagnosis
• Vitamin B12 and Folic Acid
Deficiency
• Essential element deficiency
(Copper)
• Exposure to heavy metals (lead,
arsenic & zinc)
• Drugs
• Isoniazole
• Cotrimoxazole
• Tacrolimus
• Mycophenolate mofetil
• Hereditary AD Pelger-huet anomaly
• Congenital Dyserythropoietic
anemia
• Parvovirus B19 infection
• Chemotherapy
• GCSF therapy
• Hypothyroidism
• PNH
• Autoimmune disorders
• Lymphoma Spillover
References
• Atlas & textbook of hematology, Tejinder Singh
• WHO Classification of Tumours of Hematopoietic & Lymphoid
tissues
• American Association of Pathology Atlas of Bone Marrow Pathology
• Wintrobe’s Clinical Hematology
• Williams Hematology Malignant Lymphoid Diseases

More Related Content

What's hot

Recent andvances hodgkins lymphoma
Recent andvances  hodgkins lymphomaRecent andvances  hodgkins lymphoma
Recent andvances hodgkins lymphomaSumanth Deva
 
Approach to patient with platelet disorders
Approach to patient with platelet disordersApproach to patient with platelet disorders
Approach to patient with platelet disorders
Chetan Ganteppanavar
 
Myeloproliferative disorders
Myeloproliferative disordersMyeloproliferative disorders
Myeloproliferative disorders
mukhtar ahmed
 
Acute Coronary syndrome
Acute Coronary syndrome Acute Coronary syndrome
Acute Coronary syndrome
Areej Abu Hanieh
 
T cell lymphomas ppt
T cell lymphomas pptT cell lymphomas ppt
T cell lymphomas ppt
Riddhi Karnik
 
Neuroblastoma and nephroblastoma
Neuroblastoma and nephroblastoma Neuroblastoma and nephroblastoma
Neuroblastoma and nephroblastoma
Sackler's faculty of medicine . Tel-Aviv.Uni
 
Leukaemia lecture 02 ALL transcript
Leukaemia lecture 02   ALL transcriptLeukaemia lecture 02   ALL transcript
Leukaemia lecture 02 ALL transcript
Rabiul Haque
 
Ovarian neoplasm
Ovarian neoplasmOvarian neoplasm
Ovarian neoplasm
Gaurav Gupta
 
Approach to pancytopenia .Dr ABHIJEET BARUA MD PGT.KOL.MED.CLG.
Approach to pancytopenia  .Dr ABHIJEET BARUA MD PGT.KOL.MED.CLG.Approach to pancytopenia  .Dr ABHIJEET BARUA MD PGT.KOL.MED.CLG.
Approach to pancytopenia .Dr ABHIJEET BARUA MD PGT.KOL.MED.CLG.
ABHIJEET BARUA
 
Thyroid function test , made by dr.boskey,surat
Thyroid function test , made by dr.boskey,suratThyroid function test , made by dr.boskey,surat
Thyroid function test , made by dr.boskey,surat
Boskey Gandhi
 
ECG-T wave inversion , Dr. Malala Rajapaksha ,Cardiology unit,General Hospit...
 ECG-T wave inversion , Dr. Malala Rajapaksha ,Cardiology unit,General Hospit... ECG-T wave inversion , Dr. Malala Rajapaksha ,Cardiology unit,General Hospit...
ECG-T wave inversion , Dr. Malala Rajapaksha ,Cardiology unit,General Hospit...
malala720
 
Haematopathology: An introduction to the various myeloid cell neoplasms
Haematopathology: An introduction to the various  myeloid cell neoplasmsHaematopathology: An introduction to the various  myeloid cell neoplasms
Haematopathology: An introduction to the various myeloid cell neoplasms
Qatar Cardiovascular Research Centre
 
Updated - RBC histogram
Updated - RBC histogramUpdated - RBC histogram
Updated - RBC histogram
jadcaesar
 
Cardiomyopathy 2.1 -Feisal.pptx
Cardiomyopathy 2.1 -Feisal.pptxCardiomyopathy 2.1 -Feisal.pptx
Cardiomyopathy 2.1 -Feisal.pptx
HanaaMohamedSheikhOm
 
Hyperthyroidism
HyperthyroidismHyperthyroidism
Hyperthyroidism
Suvendu Acharya
 
Thyroid disorders and heart
Thyroid disorders and heartThyroid disorders and heart
Thyroid disorders and heart
Srinivas Kinjarapu
 
Clinical Approach to Valvular heart dis
Clinical Approach to Valvular heart disClinical Approach to Valvular heart dis
Clinical Approach to Valvular heart dis
dibufolio
 

What's hot (20)

Recent andvances hodgkins lymphoma
Recent andvances  hodgkins lymphomaRecent andvances  hodgkins lymphoma
Recent andvances hodgkins lymphoma
 
Approach to patient with platelet disorders
Approach to patient with platelet disordersApproach to patient with platelet disorders
Approach to patient with platelet disorders
 
Myeloproliferative disorders
Myeloproliferative disordersMyeloproliferative disorders
Myeloproliferative disorders
 
Dyserythropoietic anaemia
Dyserythropoietic anaemiaDyserythropoietic anaemia
Dyserythropoietic anaemia
 
A Case of POEMS Syndrome
A Case of POEMS SyndromeA Case of POEMS Syndrome
A Case of POEMS Syndrome
 
Acute Coronary syndrome
Acute Coronary syndrome Acute Coronary syndrome
Acute Coronary syndrome
 
T cell lymphomas ppt
T cell lymphomas pptT cell lymphomas ppt
T cell lymphomas ppt
 
Congenital Heart Diseases
Congenital Heart DiseasesCongenital Heart Diseases
Congenital Heart Diseases
 
Neuroblastoma and nephroblastoma
Neuroblastoma and nephroblastoma Neuroblastoma and nephroblastoma
Neuroblastoma and nephroblastoma
 
Leukaemia lecture 02 ALL transcript
Leukaemia lecture 02   ALL transcriptLeukaemia lecture 02   ALL transcript
Leukaemia lecture 02 ALL transcript
 
Ovarian neoplasm
Ovarian neoplasmOvarian neoplasm
Ovarian neoplasm
 
Approach to pancytopenia .Dr ABHIJEET BARUA MD PGT.KOL.MED.CLG.
Approach to pancytopenia  .Dr ABHIJEET BARUA MD PGT.KOL.MED.CLG.Approach to pancytopenia  .Dr ABHIJEET BARUA MD PGT.KOL.MED.CLG.
Approach to pancytopenia .Dr ABHIJEET BARUA MD PGT.KOL.MED.CLG.
 
Thyroid function test , made by dr.boskey,surat
Thyroid function test , made by dr.boskey,suratThyroid function test , made by dr.boskey,surat
Thyroid function test , made by dr.boskey,surat
 
ECG-T wave inversion , Dr. Malala Rajapaksha ,Cardiology unit,General Hospit...
 ECG-T wave inversion , Dr. Malala Rajapaksha ,Cardiology unit,General Hospit... ECG-T wave inversion , Dr. Malala Rajapaksha ,Cardiology unit,General Hospit...
ECG-T wave inversion , Dr. Malala Rajapaksha ,Cardiology unit,General Hospit...
 
Haematopathology: An introduction to the various myeloid cell neoplasms
Haematopathology: An introduction to the various  myeloid cell neoplasmsHaematopathology: An introduction to the various  myeloid cell neoplasms
Haematopathology: An introduction to the various myeloid cell neoplasms
 
Updated - RBC histogram
Updated - RBC histogramUpdated - RBC histogram
Updated - RBC histogram
 
Cardiomyopathy 2.1 -Feisal.pptx
Cardiomyopathy 2.1 -Feisal.pptxCardiomyopathy 2.1 -Feisal.pptx
Cardiomyopathy 2.1 -Feisal.pptx
 
Hyperthyroidism
HyperthyroidismHyperthyroidism
Hyperthyroidism
 
Thyroid disorders and heart
Thyroid disorders and heartThyroid disorders and heart
Thyroid disorders and heart
 
Clinical Approach to Valvular heart dis
Clinical Approach to Valvular heart disClinical Approach to Valvular heart dis
Clinical Approach to Valvular heart dis
 

Similar to Myelodysplastic Syndrome.pptx

Mds csbrp
Mds csbrpMds csbrp
Mds csbrp
Prasad CSBR
 
Refreactory anemia
Refreactory anemiaRefreactory anemia
Refreactory anemia
ariva zhagan
 
myelodysplastic syndrome
myelodysplastic syndromemyelodysplastic syndrome
myelodysplastic syndrome
arvindra rahul
 
Myelodysplastic Syndrome
Myelodysplastic SyndromeMyelodysplastic Syndrome
Myelodysplastic Syndrome
Dr. Indranil Bhattacharya
 
Adult Myelodysplastic/myeloproliferative neoplasms
Adult Myelodysplastic/myeloproliferative neoplasmsAdult Myelodysplastic/myeloproliferative neoplasms
Adult Myelodysplastic/myeloproliferative neoplasms
Nilay Nishith
 
Myelodysplastic syndrome
Myelodysplastic syndromeMyelodysplastic syndrome
Myelodysplastic syndrome
Dr. Pritika Nehra
 
MDS 1.pptx
MDS 1.pptxMDS 1.pptx
MDS 1.pptx
priyankkumar59
 
PSH. usman.pptx
PSH. usman.pptxPSH. usman.pptx
PSH. usman.pptx
SaadZafar61
 
The 5th edition of the World Health Organization Classification of Haematolym...
The 5th edition of the World Health Organization Classification of Haematolym...The 5th edition of the World Health Organization Classification of Haematolym...
The 5th edition of the World Health Organization Classification of Haematolym...
Dr Seena Tresa Samuel
 
Chronic Eosinophilia Leukemia (CEL), Keganasan PMN
Chronic Eosinophilia Leukemia (CEL), Keganasan PMNChronic Eosinophilia Leukemia (CEL), Keganasan PMN
Chronic Eosinophilia Leukemia (CEL), Keganasan PMN
ssuser16dac3
 
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
College of Medicine, Sulaymaniyah
 
Hematological Malignancies 1/2
Hematological Malignancies 1/2Hematological Malignancies 1/2
Hematological Malignancies 1/2
Maya Al-khateeb
 
Approach to anemia
Approach to anemiaApproach to anemia
Approach to anemia
Chetan Ganteppanavar
 
CES 2016 02 - Acute and Chronic myeloid leukemias
CES 2016 02 - Acute and Chronic myeloid leukemiasCES 2016 02 - Acute and Chronic myeloid leukemias
CES 2016 02 - Acute and Chronic myeloid leukemias
Mauricio Lema
 
V_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_GujralV_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_Gujral
EAFO1
 
Anemia Lecture for the MLT students.pptx
Anemia Lecture for the MLT students.pptxAnemia Lecture for the MLT students.pptx
Anemia Lecture for the MLT students.pptx
TariqAlyamani2
 
Myeloid disorders
Myeloid disordersMyeloid disorders
Myeloid disorders
MohammedAlHinai18
 
acuteleukemiacomplt-161017163342 (1).pptx
acuteleukemiacomplt-161017163342 (1).pptxacuteleukemiacomplt-161017163342 (1).pptx
acuteleukemiacomplt-161017163342 (1).pptx
vandana thakur
 

Similar to Myelodysplastic Syndrome.pptx (20)

Mds csbrp
Mds csbrpMds csbrp
Mds csbrp
 
Refreactory anemia
Refreactory anemiaRefreactory anemia
Refreactory anemia
 
myelodysplastic syndrome
myelodysplastic syndromemyelodysplastic syndrome
myelodysplastic syndrome
 
Myelodysplastic Syndrome
Myelodysplastic SyndromeMyelodysplastic Syndrome
Myelodysplastic Syndrome
 
Adult Myelodysplastic/myeloproliferative neoplasms
Adult Myelodysplastic/myeloproliferative neoplasmsAdult Myelodysplastic/myeloproliferative neoplasms
Adult Myelodysplastic/myeloproliferative neoplasms
 
approach to MPN
approach to MPNapproach to MPN
approach to MPN
 
Myelodysplastic syndrome
Myelodysplastic syndromeMyelodysplastic syndrome
Myelodysplastic syndrome
 
MDS 1.pptx
MDS 1.pptxMDS 1.pptx
MDS 1.pptx
 
PSH. usman.pptx
PSH. usman.pptxPSH. usman.pptx
PSH. usman.pptx
 
The 5th edition of the World Health Organization Classification of Haematolym...
The 5th edition of the World Health Organization Classification of Haematolym...The 5th edition of the World Health Organization Classification of Haematolym...
The 5th edition of the World Health Organization Classification of Haematolym...
 
Chronic Eosinophilia Leukemia (CEL), Keganasan PMN
Chronic Eosinophilia Leukemia (CEL), Keganasan PMNChronic Eosinophilia Leukemia (CEL), Keganasan PMN
Chronic Eosinophilia Leukemia (CEL), Keganasan PMN
 
Mds
MdsMds
Mds
 
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
 
Hematological Malignancies 1/2
Hematological Malignancies 1/2Hematological Malignancies 1/2
Hematological Malignancies 1/2
 
Approach to anemia
Approach to anemiaApproach to anemia
Approach to anemia
 
CES 2016 02 - Acute and Chronic myeloid leukemias
CES 2016 02 - Acute and Chronic myeloid leukemiasCES 2016 02 - Acute and Chronic myeloid leukemias
CES 2016 02 - Acute and Chronic myeloid leukemias
 
V_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_GujralV_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_Gujral
 
Anemia Lecture for the MLT students.pptx
Anemia Lecture for the MLT students.pptxAnemia Lecture for the MLT students.pptx
Anemia Lecture for the MLT students.pptx
 
Myeloid disorders
Myeloid disordersMyeloid disorders
Myeloid disorders
 
acuteleukemiacomplt-161017163342 (1).pptx
acuteleukemiacomplt-161017163342 (1).pptxacuteleukemiacomplt-161017163342 (1).pptx
acuteleukemiacomplt-161017163342 (1).pptx
 

More from Tamil Mahizhenthi

Tubulointerstitial diseases
Tubulointerstitial diseasesTubulointerstitial diseases
Tubulointerstitial diseases
Tamil Mahizhenthi
 
Pleura Cytology
Pleura CytologyPleura Cytology
Pleura Cytology
Tamil Mahizhenthi
 
FLOW CYTOMETRY
FLOW CYTOMETRYFLOW CYTOMETRY
FLOW CYTOMETRY
Tamil Mahizhenthi
 
Ischemic heart disease
Ischemic heart diseaseIschemic heart disease
Ischemic heart disease
Tamil Mahizhenthi
 
Asthma
Asthma Asthma
Section Cutting
Section CuttingSection Cutting
Section Cutting
Tamil Mahizhenthi
 
Inborn errors of metabolism
Inborn errors of metabolism Inborn errors of metabolism
Inborn errors of metabolism
Tamil Mahizhenthi
 
GENETIC DISORDER, MUTATIONS, CYTOGENETIC DISORDERS
GENETIC DISORDER, MUTATIONS, CYTOGENETIC DISORDERSGENETIC DISORDER, MUTATIONS, CYTOGENETIC DISORDERS
GENETIC DISORDER, MUTATIONS, CYTOGENETIC DISORDERS
Tamil Mahizhenthi
 
Decalcification.pptx
Decalcification.pptxDecalcification.pptx
Decalcification.pptx
Tamil Mahizhenthi
 
Lymphoma spillover.pptx
Lymphoma spillover.pptxLymphoma spillover.pptx
Lymphoma spillover.pptx
Tamil Mahizhenthi
 
Papillary Carcinoma thyroid cytology.pptx
Papillary Carcinoma thyroid cytology.pptxPapillary Carcinoma thyroid cytology.pptx
Papillary Carcinoma thyroid cytology.pptx
Tamil Mahizhenthi
 
MEGALOBLASTIC ANEMIA.pptx
MEGALOBLASTIC ANEMIA.pptxMEGALOBLASTIC ANEMIA.pptx
MEGALOBLASTIC ANEMIA.pptx
Tamil Mahizhenthi
 
ENDOMETRIAL DATING.pptx
ENDOMETRIAL DATING.pptxENDOMETRIAL DATING.pptx
ENDOMETRIAL DATING.pptx
Tamil Mahizhenthi
 
Peripheral smear STAINING.pptx
Peripheral smear STAINING.pptxPeripheral smear STAINING.pptx
Peripheral smear STAINING.pptx
Tamil Mahizhenthi
 
HYPERSENSITIVITY.pptx
HYPERSENSITIVITY.pptxHYPERSENSITIVITY.pptx
HYPERSENSITIVITY.pptx
Tamil Mahizhenthi
 

More from Tamil Mahizhenthi (15)

Tubulointerstitial diseases
Tubulointerstitial diseasesTubulointerstitial diseases
Tubulointerstitial diseases
 
Pleura Cytology
Pleura CytologyPleura Cytology
Pleura Cytology
 
FLOW CYTOMETRY
FLOW CYTOMETRYFLOW CYTOMETRY
FLOW CYTOMETRY
 
Ischemic heart disease
Ischemic heart diseaseIschemic heart disease
Ischemic heart disease
 
Asthma
Asthma Asthma
Asthma
 
Section Cutting
Section CuttingSection Cutting
Section Cutting
 
Inborn errors of metabolism
Inborn errors of metabolism Inborn errors of metabolism
Inborn errors of metabolism
 
GENETIC DISORDER, MUTATIONS, CYTOGENETIC DISORDERS
GENETIC DISORDER, MUTATIONS, CYTOGENETIC DISORDERSGENETIC DISORDER, MUTATIONS, CYTOGENETIC DISORDERS
GENETIC DISORDER, MUTATIONS, CYTOGENETIC DISORDERS
 
Decalcification.pptx
Decalcification.pptxDecalcification.pptx
Decalcification.pptx
 
Lymphoma spillover.pptx
Lymphoma spillover.pptxLymphoma spillover.pptx
Lymphoma spillover.pptx
 
Papillary Carcinoma thyroid cytology.pptx
Papillary Carcinoma thyroid cytology.pptxPapillary Carcinoma thyroid cytology.pptx
Papillary Carcinoma thyroid cytology.pptx
 
MEGALOBLASTIC ANEMIA.pptx
MEGALOBLASTIC ANEMIA.pptxMEGALOBLASTIC ANEMIA.pptx
MEGALOBLASTIC ANEMIA.pptx
 
ENDOMETRIAL DATING.pptx
ENDOMETRIAL DATING.pptxENDOMETRIAL DATING.pptx
ENDOMETRIAL DATING.pptx
 
Peripheral smear STAINING.pptx
Peripheral smear STAINING.pptxPeripheral smear STAINING.pptx
Peripheral smear STAINING.pptx
 
HYPERSENSITIVITY.pptx
HYPERSENSITIVITY.pptxHYPERSENSITIVITY.pptx
HYPERSENSITIVITY.pptx
 

Recently uploaded

The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
Vikramjit Singh
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
Peter Windle
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Anna Sz.
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
kaushalkr1407
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
Jheel Barad
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
BhavyaRajput3
 
The French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free downloadThe French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free download
Vivekanand Anglo Vedic Academy
 

Recently uploaded (20)

The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
 
The French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free downloadThe French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free download
 

Myelodysplastic Syndrome.pptx

  • 2. Definition Group of clonal hematopoietic stem cell diseases characterised by • Cytopenia (atleast 1 lineage) • Hb < 10g/dl • Platelet count < 1 lakh/cu.mm • ANC < 1800 cells/cu.mm • Monocytes < 1000/cu.mm • dysplasia in one or more of the major myeloid lineages • Ineffective hematopoiesis • Recurrent genetic abnormalities • Increased risk of AML
  • 3. Hypoplastic MDS • 10% MDS • Independent favourable prognosis • DD – Aplastic Anemia • Exclude Acute marrow injury MDS with Fibrosis • 10 – 15% of MDS • Grade 2 – 3 fibrosis • Excess of Blasts • Aggressive clinical course • Bone marrow Biopsy > BMA • IHC for CD 34 • Different from Primary Myelofibrosis • No splenomegaly • No leucoerythroblastic blood picture • Intrasinusoidal hematopoiesis
  • 4. Epidemiology • Older adults • Male preponderance • Annual incidence = 3 – 5 caser per 1 lakh population • At least 20 cases per 1 lakh population > 70 yrs • Median age at presentation • United Kingdom – 65 yrs • India – 45 yrs • Progression to AML – 30 – 35 %
  • 5. Etiology • Hereditary • Down syndrome • Monosomy 7 • Neurofibromatosis • Congenital neutropenia • Mutagen detoxification • Family history • Fanconi Anemia • Dyskeratosis congenita • Swachman – Diamond syndrome • Diamond blackfan anemia • Acquired • Senescence • Radiation • Mutagen/genotoxic • Chemotherapy • Benzene exposure • Cigarette smoking • Agricultural solvents/chemicals • Acquired Aplastic Anemia • PNH
  • 6. Clinical Features • Anemia • Most common – 85% • Lethargy • 1/3rd transfusion dependent • Leucopenia • Neutropenia – 50% • Less common • Recurrent infections • Thrombocytopenia • 25 – 30% • Bleeding manifestations • Organomegaly • 15 – 25% • Auto immune abnormalities • Cutaneous vasculitis • Monoarticular arthritis • Percarditis • Iritis • Myositis • Pleural effusion
  • 7. Evaluation • History • Prior exposure to CT/RT • Recurrent infections • Bleeding/Bruising • Examination • Pallor/ bruising • organomegaly • Blood counts • Hb, TLC, Platelet count • RC • Blood film • BMA + BM Bx • IHC • CD 34 • CD 41 • CD 61 • Immunophenotyping of BM • Bone marrow cytogenetics • Biochemical tests • S. Iron • S. LDH • TSH • Red cell folate & S. B12 • Other tests • Viral markers • Autoimmune disease work up • FLAER for PNH
  • 8. Exclusion of reactive causes of Dysplasia • Megaloblastic Anemia • HIV Infection • Recent cytotoxic therapy • Alcoholism • Severe intercurrent illness
  • 9. Microscopy – Points to remember • >2 hrs from collection – specimen unsatisfactory • Staining is significant • Don’t diagnose MDS without detailed history • No of cells to count • PS – 200 cells • BM – 500 cells • If Cytopenic - Count from buffy coat • PS blasts can be more than BM blasts in 13% of MDS • Persistent cytopenia without dysplasia – Idiopathic cytopenia of undetermined significane • MDS associated clonal gene mutations without dysplasia – clonal hematopoiesis of indeterminate potential • If in doubt – observe patient for 6 months before diagnosis
  • 10. PS Characteristics of dysplasia - RBC • Ovalocytosis • Macrocytosis • Elliptocytosis • Stomatocytes • Tear drop cells • Nucleated red cells • Basophilic stippling • Howell-Jolly bodies
  • 11. PS Characteristics of Dysplasia - WBC • Hypolobation • Hyposegmentation – Pince-nez type • Hypogranulation • Ring shaped nuclei • Pseudo-Pelger Huet anomaly - marked clumping of nuclear chromatin – nuclear hypolobation • Auer rod • Irregular contour of nuclei • Blasts
  • 12. PS Characteristics of dysplasia - Platelets • Giant platelets • Hypogranular platelets • Agranular platelets
  • 13. Bone Marrow Aspiration – Hypercellular
  • 14. BMA Characteristics of dysplasia - RBC • Megaloblastic erythropoiesis • Nuclear budding of erythroblasts • Multinucleation • Karyorrhexis • Ring sideroblasts • > 5 iron granules • Encircling > 1/3rd nucleus • Cytoplasmic vacuolation – PAS +ve • Increased Iron stores
  • 15. BMA Characteristics of dysplasia - WBC • Defective granulation • Presence of Auer Rods in myeloid cells • Maturation arrest at myelocyte stage • Increase in Monocytoid cells • ALIP • Very small/large granules • Pseudo chediak higashi granules – Abnormal large granular clumping • Irregular nuclear hypersegmentation • CD 34 +ve blasts
  • 16. BMA Characteristics of dysplasia - Platelets • >10% Micromegakaryocytes* • < 15 µm - Size of promyelocyte • Non/bi lobated nucleus • Eosinophilic cytoplasm • Hypogranulation of megakaryocytes • Mutliple small nuclei of megakaryocytes – Pawn ball • Nuclear Hypolobation • CD 61 & CD 41 +ve
  • 17. Bone Marrow Trephine Biopsy • Cellularity of Marrow • ALIP • Reticulin Fibrosis – 20% • Megakaryocyte Dysplasia • CD 61 • CD 41 • Lymphoid aggregates • Hypoplastic MDS • Neovascularisation – transformation to AML ALIP Blasts in cell clusters located away from bone trabeculae & Vascular structures CD 34 +
  • 18. IHC Immature, Blast cells CD 34 TdT CD 117 Erythroblasts Glycophorin A Megakaryoblasts CD 61 CD 41 Apoptotis Markers TNF – Alpha Bax
  • 19. Immunophenotype • Flow cytometry in CD 34+ve cells • Aberrant maturation patterns in granulopoiesis can predict morphological dysplasia • Myeloblasts, monocytoid cells & maturing myeloid cells – typical expression related to lineage & stage of maturation • In MDS • Increased/ Decreased expression of normal antigens • Asynchronous maturational expression • Aberrant antigen expression • Atleast 3 aberrancies +
  • 20.
  • 21. Genetic profile • Isolated 5q deletion alone & 5q deletion + one additional abnormality • Hypo/non – lobated megakaryocytes • Macrocytic anemia • Favourable clinical course • Loss of 17 p • pseudo pelget huer anomaly • TP 53 mutation • Therapy related • Unfavourable clinical course Conventional Karyotyping Multicolour FISH Gene sequencing SNP Array
  • 22. Genetic profile • Normal Karyotype • 50% MDS • Abnormal Karyotype • 90% - t-MDS • 40 – 50% - primary MDS
  • 24. Pathogenesis • Aberrations in apoptotic mechanisms – Increased Apoptosis • Increased Proliferation • Ineffective Hematopoiesis • Autocrine production of Angiogenic molecules – Expansion of leukemic clone
  • 25. Classification – WHO 2016 Name Dysplasia Cytopenia RS in BM PS blasts BM Blasts MDS - SLD 1 1 – 2 < 15%SF3B1 <1% <5% MDS - MLD 2 – 3 1 – 3 MDS – RS – SLD 1 1 – 2 >15%SF3B1 MDS – RS - MLD 2 – 3 1 – 3 MDS with isolated del (5q) 1 – 3 1 – 2 None or any MDS – EB1 1 – 3 1 – 3 <5% <10% MDS – EB2 1 – 3 1 – 3 <20% <20%
  • 26. MDS - U Name Dysplasia Cytopenia RS PS Blasts BM Blasts With 1% Blood blasts 1 – 3 1 – 3 None or any 1%ON 2 OCC <5% With SLD & Pancytopenia 1 3 <1% <5% Based on defining cytogenetic abnormality 0 1 – 3 <15%MDS-RS-SLD
  • 27. FAB Classification Subtype Abbreviation PS –Blasts BM Refractory Anemia RA < 1% Blasts < 5% + RS < 15% RA + Ringed Sideroblasts RARS < 1% Blasts < 5% + RS > 15% RA + Excess blasts RAEB < 5% Blasts 5 – 20% RA + Excess blasts in transformation RAEB – t >5% Blasts 20 – 30 % (Auer rods) Chronic myelomonocytic leukemia CMML <5% + Monocytes > 1000/cu.mm Any of the above Acute Myeloid Leukemia AML Variable Blasts > 30 %
  • 28. MDS – Single lineage dysplasia • Incidence : 7 – 20% MDS • Definition • Unexplained cytopenia/ bicytopenia • > 10% dysplastic cells in one myeloid lineage • 2008 edition – Refractory cytopenia with unilineage dysplasia • Refractory anemia • Refractory neutropenia • Refractory thrombocytopenia • Ringed sideroblasts • < 15% • <5% in cases with SF3B1 mutation No correlation between cytopenia & dysplasia
  • 29. MDS – Multi lineage dysplasia • 1 or >1 cytopenia • 2 or >2 dysplasia in the myeloid lineages (> 10%) • 200 erythroid, 200 Neutrophil precursors & 30 megakaryocytes (30 – 40%) to be examined in the BMA or BM Bx • Blasts • Peripheral smear - < 1% • Bone marrow - <5% • Auer rods – Absent • Monocyte count - < 1000 cells/cu.mm • Marrow fibrosis – 16% Incidence 30% of all cases 48% of cases without excess blasts 65% along with MDS – RS – MLD
  • 30. MDS with Ringed sideroblasts • Incidence: 3 – 11 % • >15% ringed sideroblasts in the bone marrow • >5% in case of SF3B1 mutation • Other subtypes to be excluded • MDS – RS – SLD – Usually anemia + Erythroid Dysplasia (9982/3) • MDS – RS – MLD – any number of cytopenias / dysplasias (9993/3)
  • 31. MDS with Excess Blasts • < 20% in both Bone Marrow (5 – 19%) & Blood ( 2 – 19%) • Incidence – 40% • Hypercellular marrow • 30 – 50% have clonal genetic abnormalities EB 1 EB 2 PS Blasts 2 – 4 % 5 – 19% BM Blasts 5 – 9 % 10 – 19 % Auer rods Absent Present Progression to AML 25% 33% Median Survival 16 months 9 months
  • 32. Variants MDS EB & Erythroid Predominance • Maturing Erythroblasts > 50% of marrow cells • Myeloblasts > 20% of non erythroid nucleated cells MDS EB & Fibrosis • 15% show significant degree of fibrosis • Therapy related MDS • Presence of excess blasts confirmed by IHC – CD 34 • Increased dysplastic megakaryocytes • FCM – CD 34 & C-KIT +ve
  • 33. MDS with isolated del 5q • Anemia + other cytopenia + Thrombocytosis • Thrombocytosis in 1/3rd – ½ of cases • Loss of tumour suppressor genes in the minimally deleted region (q31 – q33) • Erythroid hypoplasia • Dysplastic Megakaryocytic hyperplasia • Del 5q demonstrated by FISH analysis • Cases with addl monosomy 7/ Del 7q is included in this category • Subsets show JAK2 V617F mutation & SF3B1 mutation • Median survival – 66 – 145 months • AML transformation < 10 %
  • 34. MDS - Unclassifiable • Diagnosed by Exclusion • Incidence : 6.3% of cases with <5% blasts • 1% blasts in the blood on 2 separate occasions • Persistent cytopenia • < 2% Blasts in blood • < 5% blast in BM • < 10% Dysplasia • Prognosis in cases with 1% blasts • Median survival – 30 months • AML Progression – 14%
  • 35. Childhood MDS • < 5% of all hematopoietic neoplasms in less than 14 yrs • Subtypes • Refractory Cytopenia of childhood (Blasts <5% in BM & <2% in PS) • Conventional MDS • MDS – EB • MDS – RS • T - MDS • GATA2 germline mutation is present in 7% primary MDS • Criteria for diagnosis - MDS (atleast 2) • Sustained unexplained cytopenia • Bilineage morphologic dysplasia • Acquired clonal cytogenetic morphology • Increased blasts (>5%)
  • 36. Therapy related MDS • Late complication of Chemotherapy/ radiotherapy administered for prior neoplastic or non neoplastic disorder • Incidence: 10 – 20% of all cases of AML, MDS & MDS/MPN • Prior history • 70% for solid tumours (Breast Cancer) • 30% Hematopoietic neoplasms (Non Hodgkin’s lymphoma) • Poor Prognosis
  • 39.
  • 40. Very low Low Intermediate High Very High Patients % 19% 38% 20% 13% 10% Survival 8.8 5.3 3.0 1.6 0.8 AML transformation Not reported 10.8 3.2 1.4 0.7
  • 41. Differential Diagnosis • Vitamin B12 and Folic Acid Deficiency • Essential element deficiency (Copper) • Exposure to heavy metals (lead, arsenic & zinc) • Drugs • Isoniazole • Cotrimoxazole • Tacrolimus • Mycophenolate mofetil • Hereditary AD Pelger-huet anomaly • Congenital Dyserythropoietic anemia • Parvovirus B19 infection • Chemotherapy • GCSF therapy • Hypothyroidism • PNH • Autoimmune disorders • Lymphoma Spillover
  • 42. References • Atlas & textbook of hematology, Tejinder Singh • WHO Classification of Tumours of Hematopoietic & Lymphoid tissues • American Association of Pathology Atlas of Bone Marrow Pathology • Wintrobe’s Clinical Hematology • Williams Hematology Malignant Lymphoid Diseases